Owing to the absence of significant differences in OS in these trials examining the role of LEV and IFN in the adjuvant setting of colon cancer, continuation of accrual in the present trial was considered as ethically justifiable until the end of the accrual period in 1999. The gene discussed is IFNA1; the disease is malignant colon neoplasm.